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Cohort profile
AbstrACt
Purpose The aim of this article is to provide a detailed 
description of the ongoing nationwide Danish Centre 
for Strategic Research in Type 2 Diabetes (DD2) project 
cohort and biobank. The DD2 cohort continuously 
enrols newly diagnosed patients with type 2 diabetes 
(T2D) throughout Denmark. The overall goal of the 
DD2 project is to establish a large and data-rich T2D 
cohort that can serve as a platform for exhaustive 
T2D research including (1) improved genotypic and 
phenotypic characterisation of T2D, (2) intervention 
studies of more individualised T2D treatment, (3) 
pharmacoepidemiological studies and (4) long-term 
follow-up studies on predictors of T2D complications 
and prognosis.
Participants Between 2010 and 2016, 7011 individuals 
with T2D have been enrolled and assessed at baseline. 
Information collected include interview data (eg, body 
weight at age 20 years, physical activity and alcohol 
consumption), clinical examination data (eg, hip–waist 
ratio and resting heart rate) and biological samples 
(whole blood, DNA, plasma and urine) stored at −80°C 
and currently analysed for a range of biomarkers and 
genotypes.
Findings to date Registry linkage has provided 
extensive supplemental continuous data on glycosylated 
haemoglobin A, lipids, albuminuria, blood pressure, 
smoking habits, body mass index, primary care contacts, 
hospital diagnoses and procedures, medication use, 
cancer and mortality. Cross-sectional associations 
between biomarkers, family history, anthropometric and 
lifestyle measures and presence of complications at 
baseline have been reported.
Future plans During 2016, a detailed follow-up 
questionnaire has been answered by 85% of initial 
participants, providing follow-up information on baseline 
variables and on presence of diabetic neuropathy. The 
DD2 cohort has now been followed for a total of 18 862 
person-years, and nested intervention trials and follow-
up studies are ongoing. In the future, the cohort will 
serve as a strong national and international resource for 
recruiting patients to nested case studies, clinical trials, 
postmarketing surveillance, large-scale genome studies 
and follow-up studies of T2D complications.
IntroduCtIon 
Type 2 diabetes (T2D) is associated with a wide 
range of devastating complications, classically 
including cardiovascular disease, end-stage 
renal disease, blindness, diabetic foot ulcers 
and amputations. T2D also increases risk of 
infections, some cancers and neuropsychi-
atric disease.1 These complications inflict a 
burden on the healthcare system as well as on 
the individual patients with diabetes. Since it 
is hard to prevent T2D, there is a compelling 
strengths and limitations of this study
 ► The Danish Centre for Strategic Research in Type 2 
Diabetes (DD2) project cohort is an ongoing Danish 
cohort and biobank of newly diagnosed patients 
with type 2 diabetes (T2D) continuously enrolled on 
a nationwide level since 2010.
 ► By 2016, 7011 patients have been recruited from 
general practitioners (53%) and hospital specialist 
outpatient clinics (47%).
 ► The cohort includes baseline interview data, phys-
ical examination data, biological samples (DNA, 
blood and urine) as well as baseline and follow-up 
data on glycosylated haemoglobin A, lipids, albu-
minuria, blood pressure, smoking habits, body mass 
index, primary care contacts, hospital diagnoses and 
procedures, medication use, incident cancers, mor-
tality and causes of death.
 ► The cohort may represent patients with more ad-
vanced T2D than average, and 85% already had ini-
tiated glucose-lowering treatment at enrolment that 
hampers studies of drug-naive patients with T2D.
 ► In the future, the DD2 cohort will serve as a strong 
national and international resource for recruiting 
patients to nested clinical trials, large-scale ge-
nome studies and long-term follow-up studies of 
T2D complications through linkage with the large 
network of existing population-based registries in 
Denmark.
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need for cost-effective research to target and improve 
diabetes treatment in order to prevent complications. 
Fortunately, over the last decades, the number of avail-
able glucose-lowering treatment options has increased,2 
facilitating individually tailored treatment. In this context 
determining how genotype and phenotype may influence 
the optimal choice of treatment is essential.3 
Denmark has a tax-supported healthcare system that 
includes free access to care at general practitioners (GPs) 
and hospitals as well as partial reimbursement for most 
prescribed drugs, including diabetes drugs.4 GPs—the 
gatekeepers of the Danish National Health Service—are 
responsible for nearly all referrals to hospitals and special-
ists. Patient contacts with health and social services are 
extensively documented at the individual level in national 
databases using the unique civil personal registration 
number (CPR number) that has been assigned since 1968 
to all Danish residents at birth or on immigration.4
In this setting, the nationwide Danish Centre for Stra-
tegic Research in Type 2 Diabetes (DD2) project was estab-
lished in 2010. The Project’s overall goal is to provide an 
international resource for T2D research. It encompasses 
establishment of the nationwide and data-rich DD2 cohort 
and a linked biobank of DNA, blood and urine. The study 
rationale has been to provide a platform for improved 
genotypic and clinical characterisation of T2D, for devel-
oping more individualised treatment and for testing new 
antidiabetic drugs in nested intervention studies. More-
over, to establish a unique T2D patient cohort by linkage 
with the large network of existing population-based regis-
tries in Denmark, through which patients can be followed 
longitudinally for a variety of clinical and socioeconomic 
outcomes for decades, allowing improved understanding 
of the predictors of long-term diabetes prognosis.
The aim of this cohort profile paper is to provide a 
description of the DD2 cohort as an international T2D 
research resource, including an overview of the collected 
data and a description of the baseline characteristics.
Cohort desCrIPtIon
study participants and recruitment
Since 1 January 2009, all patients with newly or recently 
diagnosed T2D in Denmark have been eligible to partic-
ipate in the DD2 cohort. The first patient was enrolled 
in November 2010, and the cohort now consists of 7011 
patients. The DD2 project is ongoing, with continuous 
enrolment.
The process of enrolling in the DD2 cohort has been 
described in detail elsewhere5: (1) clinical providers 
(usually either the patient’s GP or a hospital physician/
nurse) identify patients newly diagnosed with T2D in 
routine clinical practice. (2) Those patients are informed 
by the clinical provider about the existence of the DD2 
project. (3) Patients interested in participating receive 
detailed oral and written information and are asked to 
sign a written informed consent document for enrolment. 
(4) Patient clinical information is then collected: GPs or 
hospital physicians/nurses complete an online question-
naire, including items requiring a physical examination. 
(5) Urine and fasting blood samples are collected for 
storage in a biobank.6
Approximately 80% of patients with T2D in Denmark 
receive care at GPs’ offices and the remainder at hospital 
specialist outpatient clinics. Enrolment into the DD2 
cohort takes place in both settings (figure 1). From 
2010 to 2012, most patients were enrolled at hospital 
outpatient clinics rather than at GP offices (1559 vs 739 
patients). From 2013 on, the number of patients recruited 
by GPs increased rapidly,7 reaching 3688 in February 
2016. As of that month, the corresponding number of 
patients recruited by outpatient specialist clinics was 3323 
(table 1).
During the entire DD2 enrolment period, all diag-
nosing of T2D in routine clinical practice has been 
made according to WHO criteria, before 2012 primarily 
based on OGTT and after 2012 primarily based on glyco-
sylated haemoglobin A (HbA1c) >48 mmol/mol (6.5%). 
No further diagnostic criteria for enrolment have been 
applied in the DD2 project. The DD2 project explic-
itly aims to comprehensively study T2D as diagnosed in 
everyday clinical care, as one of the project aims is to 
document pitfalls in initial T2D diagnosing, including 
investigation of subtypes and subphenotypes in the 
cohort, occurrence of secondary diabetes, autoimmune 
diabetes and so on.
While the DD2 cohort from the beginning aimed to 
focus on newly diagnosed T2D patients, in clinical prac-
tice, the referral to DD2 may not happen at first diabetes 
notice when other clinical activity may be more pertinent. 
Individuals who have had prevalent T2D for some time 
after 2009 are also accepted for participation. While we 
do not have complete data on exact date of diabetes diag-
nosis for all individuals, average time from first recorded 
glucose-lowering drug initiation to enrolment date in the 
DD2 cohort is 1–1.5 years.
The exact proportion of all patients with incident 
T2D in Denmark that is enrolled into the DD2 cohort 
is unknown. With an average enrolment in the order 
of 1000–1200 DD2 patients per year, the project enrols 
an estimated 5% of newly diagnosed patients with T2D 
nationwide.
The number of enrolled patients and recruitment sites 
vary across the five Danish healthcare regions. Currently, 
the largest proportion (35%) of the cohort patients has 
been recruited from the region of Southern Denmark, 
which comprises 21% of Denmark’s population, followed 
by the Central Denmark Region (with 24% of cohort 
patients) and the Capital Region (with 19% of cohort 
patients), comprising 22% and 31% of Denmark’s popu-
lation, respectively.
Loss of patients from the DD2 cohort can occur due 
to emigration and death. These events are identified by 
linkage to the Danish Civil Registration System (CRS), 
which has recorded vital status for the entire Danish popu-
lation since 1968, with daily electronic updates.4 Enrolled 
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patients have the right to withdraw from the DD2 cohort, 
but only four individuals have done so thus far.
data collection
Baseline data recorded in the DD2 database include 
each patient’s CPR number, date of enrolment and DD2 
variables collected directly at the enrolment visit (inter-
view data, clinical examination data and biobank data). 
Furthermore, linkage with a wide range of Danish health 
and administrative registries, including the Danish 
Diabetes Database for Adults (DDDA), one of several 
Danish nationwide public clinical quality improvement 
registries,7 ensures important additional baseline data 
(figure 2).
The cohort is followed prospectively through linkage 
with the DDDA and other Danish administrative and 
health registries. Moreover, directly collected data are 
used to follow DD2 patients for outcomes not routinely 
available in medical registries as described below.
Directly collected DD2 baseline variables
These include waist–hip ratio, recalled body weight at 
age 20 years, maximum lifetime body weight, alcohol 
consumption, family history of diabetes, resting heart 
Figure 1 Enrolment sites throughout Denmark. Every circle represents an enrolment site, either at a general practitioner’s 
office or at an outpatient clinic. The administrative headquarter of the DD2 is in Odense (red dot). DD2, Danish Centre for 
Strategic Research in Type 2 Diabetes.
Table 1 Geographical distribution of DD2 participants by recruitment setting and year of enrolment
Region
Hospital outpatient clinics, N General practitioners’ offices, N
2010 2011 2012 2013 2014 2015 2016 Total 2011 2012 2013 2014 2015 2016 Total
Capital 0 23 246 197 199 85 5 755 7 144 259 134 39 5 588
Central Denmark 18 211 356 299 222 195 7 1308 0 38 192 84 72 5 391
North Denmark 0 2 52 16 73 19 5 167 0 31 276 161 30 0 498
Zealand 0 0 0 6 20 4 0 30 3 1 432 239 71 11 757
Southern 
Denmark
0 334 303 168 160 93 5 1063 184 324 237 147 471 50 1413
Unspecified – – – – – – – – – 2 29 7 1 2 41
Total Denmark 18 570 957 686 674 396 22 3323 194 540 1425 772 684 73 3688
DD2, Danish Centre for Strategic Research in Type 2 Diabetes.
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rate, physical activity level and (added in 2015) self-re-
ported date of first T2D diagnosis. The self-reported phys-
ical activity level is currently being validated by placing 
accelerometers (AX3, Axivity, Newcastle, UK) directly on 
the skin of the thigh and back of persons in a subcohort 
of DD2 participants (n=1000), and all physical activity is 
recorded over a 10-day period. Moreover, a smartphone 
application (www. interwalk. dk) holding an interval-based 
training program has been developed. DD2 participants 
are encouraged to download and use this application, 
which guides and monitors their physical exercise. The 
logged exercise data are then transferred to the DD2 
cohort and allow future investigations of for example, the 
impact of exercise on risk of T2D complications. Urine 
and blood samples (whole blood, serum, plasma and 
purified DNA) are stored in a biobank6 and can be used 
for myriad purposes. To date, plasma samples have been 
analysed for a number of baseline variables, including 
fasting blood glucose, C-peptide (used in homeostatic 
model assessment of insulin resistance), glutamic acid 
decarboxylase antibodies, alanine-aminotransferases 
(ALAT), amylase and C reactive protein (CRP). Several 
currently initiated and planned studies will provide a 
larger range of analysed biobank variables. For instance, 
DNA has been purified from 6000 patients and ‘matu-
rity-onset diabetes of the young’ (MODY) genes are 
now being sequenced in order to identify individuals 
carrying likely pathogenic variants. As well, studies of 
the prevalence of ‘latent autoimmune diabetes in adults’ 
in cohort members and the impact of the inflammatory 
system on diabetic complications have been initiated and 
will lead to analyses of additional biomarkers, including 
mannan-binding lectin.
Variables provided by the DDDA
The DDDA, established in 2005, provides a key source of 
supplemental individual-level data.7 Quality of care data 
(variables outlined below) are submitted from GP offices 
and outpatient clinics to the DDDA annually or bienni-
ally. The DDDA thus can provide baseline and follow-up 
data for members of the DD2 cohort including data on 
the T2D diagnosis date first recorded in the healthcare 
system, tobacco smoking, completion of examinations 
for diabetic foot and eye disease, body mass index (BMI), 
physician-reported antidiabetic treatment, antihyperten-
sive treatment, hypolipidaemic treatment and routine 
laboratory measurements such as HbA1c, plasma lipids 
and albuminuria.
Administrative and health registries
Migration and civil status can be ascertained from the 
CRS4 (figure 3). The Danish National Patient Registry 
(DNPR)8 maintains complete data on all hospital admis-
sions since 1977 and on all hospital outpatient clinic and 
emergency room contacts since 1995, including dates of 
admission and discharge, visit dates, surgical procedures 
Figure 2 Flow chart of data collection in the DD2 cohort study. DD2, Danish Centre for Strategic Research in Type 2 Diabetes; 
DDDA, Danish Diabetes Database for Adults; HbA1c, glycosylated haemoglobin A; SF-12, 12-Item Short Form Health Survey.
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performed and primary and secondary discharge diag-
noses coded according to the International Classification of 
Diseases, 8th Revision until the end of 1993 and 10th Revi-
sion thereafter. Linkage to the DNPR makes it possible 
to obtain individual-level information at baseline and 
during follow-up on diseases and treatments relevant to 
diabetes, such as cardiovascular events, microvascular 
complications and dialysis. On the basis of diagnoses in 
the DNPR, the baseline comorbidity burden of each DD2 
participant is calculated using Charlson Comorbidity 
Index (CCI) scores9 (low: 0 points, medium: 1–2 points, 
high ≥3 points; diabetes is excluded as it constitutes the 
index disease). Linkage to the Danish National Health 
Service Prescription Database (DNHSP)10 provides indi-
vidual-level information on reimbursable drugs dispensed 
at all pharmacies in Denmark allowing to track treatment 
history of each DD2 participant. Pharmacy data include 
the date of dispensing, as well as amount and type of 
drug prescribed according to the Anatomical Thera-
peutic Chemical classification system. The Danish Cancer 
Registry (DCR)11 has recorded data on cancer diagnoses 
in Denmark since 1943 and is a valuable resource for 
studying cancer in patients with T2D. Linkage to the 
Danish Register of Causes of Death (DRCD)12 allows 
evaluation of cause-specific mortality, while linkage to 
the Statistics Denmark database provides socioeconomic 
data, for example, on education, job level and income. 
The National Health Insurance Service Registry contains 
information on all services provided by GPs and special-
ists in Denmark since 1990, including physiotherapists, 
dentists and chiropractors. Data on services include the 
number of contacts, health service provider and type of 
service (eg, consultation, blood glucose measurement or 
vaccination).13
Questionnaire data 2016
By June 2016, all enrolled DD2 patients were sent ques-
tionnaires to gather follow-up data (described below) as 
well as data on the prevalence of diabetic neuropathy. 
Neuropathy-related questions included, among others, 
the Michigan Neuropathy Screening Instrument ques-
tionnaire, the Douleur Neuropathique 4 questionnaire 
and other pain-related questions. A random sample of 
patients reporting symptoms of painful and non-painful 
neuropathy as well as a random sample of control patients 
without symptoms will be invited for an in-depth neurop-
athy examination during 2016–2018, which will allow 
comprehensive investigation of this late diabetic compli-
cation. The questionnaires also maintained follow-up 
questions regarding the lifestyle factors included in the 
baseline study interview, including alcohol use, smoking 
habits and physical activity (figure 2). Preliminary data 
from this questionnaire survey have revealed a remark-
able response rate of 85%.
Also, quality of life 12-Item Short Form Health Survey 
(SF-12) questionnaires have recently been emailed to 
all DD2 cohort members with a known email address 
(n=2629). As of August 2016, 1002 patients (38% of those 
with email addresses) had responded to this question-
naire. Follow-up SF-12 questionnaires will be emailed 
automatically every second year.
baseline characteristics of study participants
An overview of the interview and clinical examination 
data collected from the 7011 patients enrolled in the DD2 
between November 2010 and February 2016 is provided 
in table 2.
As of February 2016, the DD2 cohort consisted of 
4065 (58%) men, the median age was 61 years (IQR: 
Figure 3 Schematic overview of individual-level data linkage in the DD2 cohort using the civil registration number as personal 
identification. DD2, Danish Centre for Strategic Research in Type 2 Diabetes.
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52–68 years) and 3717 (53%) patients had a known 
family history of diabetes. In regard to exercise, 1161 
patients (17%) reported less than 30 min and 1897 
patients (27%) reported at least 30 min of physical 
activity 7 days per week. Overall, 2748 patients (39%) 
reported regular sports activities. At baseline, 7% 
(n=472) consumed more alcohol per week than the 
recommended maximum safe amount in Denmark 
(maximum of 14/21 drinks per week for women/
men). Weight at 20 years of age was available for 6082 
study participants, with a median value of 70 kg (IQR: 
60–80 kg). The median value of maximum lifetime 
weight was 100 kg (IQR: 86–115 kg) in the cohort. 
Median waist–hip ratios were 1.02 (IQR: 0.97–1.06) 
in men and 0.92 (IQR: 0.87–0.97) in women. To 
date, biological samples have been obtained from 
more than 93% of cohort members, with a median 
fasting blood glucose measurement of 7.1 mmol/L 
(minimum–maximum: 2.5–29 mmol/L) and a median 
C-peptide measurement of 1161 pmol/L (IQR: 
865–1570 pmol/L).14
By September 2015, 5115 patients (73%) had been 
linked to the DDDA quality-of-care database (table 3).
Of the 3835 patients with a known BMI value, 37% 
of men were overweight at DD2 enrolment and 52% 
were obese, while 29% of women were overweight and 
55% were obese. Seventeen per cent (n=886) were 
Table 2 Characteristics of patients with newly diagnosed 
type 2 diabetes enrolled in the Danish Centre for Strategic 
Research in Type 2 Diabetes (DD2) project during November 
2010–February 2016
Variables
Patients with 
type 2 diabetes
Persons enrolled in DD2 by February, 
2016, n (%)
7011 (100)
  Enrolled from general practitioners’ 
offices, n (%)
3688 (53)
  Enrolled from hospital clinics, n (%) 3323 (47)
Median age (IQR), years 61 (52–68)
Minimum–maximum age, years 17–95
Gender, n (%)
  Male 4065 (58)
  Female 2946 (42)
Resting heart rate, median (IQR) 70 (63–79)
Waist circumference, median
(IQR), cm
106 (97–116)
Waist–hip ratio in men, median (IQR) 1.02 (0.97–1.06)
Waist–hip ratio in women, median (IQR) 0.92 (0.87–0.97)
Median weight at 20 years of age (IQR), kg 70 (60–80)
  Weight unknown at age 20, n (%) 929 (13)
Median maximum lifetime weight (IQR), kg 100 (86–115)
  Maximum lifetime weight unknown, n 
(%)
75 (1)
Alcohol use, n (%)
  Maximum 14/21 drinks/week (women/
men)
6539 (93)
  More than 14/21 drinks/week (women/
men)
472 (7)
Days per week with 30+ min of physical 
activity (days)
  0 1161 (17)
  1 488 (7)
  2 891 (13)
  3 954 (14)
  4 622 (9)
  5 681 (10)
  6 317 (5)
  7 1897 (27)
Regular sports activities, n (%)
  Yes 2748 (39)
  No 4262 (61)
Level of physical activity during the past 
year, n (%)
  Hard physical training and competitive 
sports several times a week
55 (1)
  Leisure sports, heavy garden work or 
similar activity at least 4 hours per week
1370 (20)
Continued
Variables
Patients with 
type 2 diabetes
  Walking, cycling or other light exercise 
at least 4 hours per week
4298 (61)
  Reading, television watching or other 
sedentary activity
1288 (18)
Family history of diabetes, n (%)
  Yes 3717 (53)
  No 2696 (39)
  Don’t know 598 (9)
Median fasting blood glucose (IQR), 
mmol/L*
7.1 (6.4–8.3)
Median C-peptide†‡ (IQR), pmol/L 1161 (865–
1570)
Glutamic acid decarboxylase antibodies§
  ≤30 kU/L, N (%) 5655 (97)
  >30 kU/L, N (%) 161 (3)
Median alanine-aminotransferases¶ (IQR), 
U/L
27 (20–38)
Median pancreatic amylase¶ (IQR), U/L 23 (16–30)
Median C reactive protein¶ (IQR), mg/L 2.1 (1.0–4.8)
*Currently analysed for the first consecutive 5363 DD2 patients.
†Reference range: 400–1600 pmol/L.
‡Currently analysed for the first consecutive 5800 DD2 patients.
§Currently analysed for the first consecutive 5816 DD2 patients.
¶Currently analysed for the first consecutive 1018 DD2 patients.
Table 2 Continued 
 o
n
 14 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017273 on 7 April 2018. Downloaded from 
7Christensen DH, et al. BMJ Open 2018;8:e017273. doi:10.1136/bmjopen-2017-017273
Open Access
current daily smokers, and 32% (n=1649) were former 
smokers. Most had an HbA1c value below 7.0% (70%) 
and 4358 (85%) had received antidiabetic treatment 
within the year prior to enrolment; 59 patients (1%) 
were taking only insulin and 3993 (78%) received only 
oral antidiabetic treatment, as confirmed by routine 
prescription data from DNHSP. A diabetic eye exam-
ination had been performed on 2762 (54%) cohort 
members and a foot examination on 4362 (85%). At 
DD2 enrolment, microalbuminuria was present in 16% 
of patients, and macroalbuminuria was present in 2%. 
Median systolic/diastolic blood pressure was 130/80, 
and 3523 patients (69%) were being treated for 
hypertension. Median total cholesterol was 4.4 (IQR: 
3.7–5.1) mmol/L; 3373 patients (66%) were receiving 
hypolipidaemic treatment. Linkage of the DD2 cohort 
to the DNPR and DNHSP revealed that approximately 
one-third of patients had hospital-diagnosed comor-
bidity (CCI score ≥1 point) prior to enrolment. Twen-
ty-two per cent had hospital-diagnosed macrovascular 
disease, and 15% had microvascular complications 
prior to enrolment (table 4).
Table 3 Characteristics of 5115 patients enrolled in the 
nationwide Danish Centre for Strategic Research in Type 2 
Diabetes (DD2) project, which currently can be linked to the 
Danish Diabetes Database for Adults
Variables
Patients 
with type 2 
diabetes
N (%) of DD2 participants who could be 
linked to the Danish Diabetes Database 
for Adults, as of September 2015.
5115 (73)
Tobacco smoking, n (%)
  Never smoker 2254 (44)
  Former smoker 1649 (32)
  Current smoker, daily 886 (17)
  Current smoker, occasionally 55 (1)
  Smoking status listed as unknown 271 (5)
Men (n=2984)
Median height (IQR), cm 178 (174–183)
  Height missing, n (%) 709 (24)
Current median weight (IQR), kg 96 (85–110)
  Weight missing, n (%) 229 (8)
Current BMI, n (% of those with known BMI)
  <18.5 2 (0)
  18.5–24.9 250 (11)
  25–29.9 833 (37)
  30+ 1183 (52)
  BMI missing 716
Women (n=2131)
Median height (IQR), cm 164 (160–169)
  Height missing, n (%) 561 (26)
Current median weight (IQR), kg 84 (71–96)
  Weight missing, n (%) 188 (4)
Current BMI, n (% of those with
known BMI)
  <18.5 8 (1)
  18.5–24.9 240 (15)
  25–29.9 458 (29)
  30+ 861 (55)
  BMI missing 564
HbA1c value
  <7% 3592 (70)
  7.0%–8.0% 824 (16)
  8.0%–9.0% 303 (6)
  ≥9.0% 313 (6)
  HbA1c missing 83 (2)
Albuminuria, N (%)
  Albumin–creatinine ratio <30 mg/g 3565 (70)
  Albumin–creatinine ratio 30–300 mg/g 830 (16)
  Albumin–creatinine ratio ≥300 mg/g 110 (2)
Continued
Variables
Patients 
with type 2 
diabetes
  Albuminuria–creatinine ratio missing 610 (12)
Blood pressure, median (IQR), mm Hg
  Systolic 130 (124–140)
  Diastolic 80 (74–85)
Lipids, median (IQR), mmol/L
  Total cholesterol 4.4 (3.7–5.1)
  HDL cholesterol 1.2 (1.0–1.5)
  LDL cholesterol 2.2 (1.7–2.8)
  Triglycerides 1.6 (1.2–2.4)
Physician-reported antidiabetic treatment, n 
(%)*
  Insulin only 59 (1)
  Insulin and oral antidiabetic treatment 306 (6)
  Oral antidiabetic treatment 3993 (78)
  None 757 (15)
Physician-reported antihypertensive 
treatment, n (%)
3523 (69)
Physician-reported ACE inhibitor or ATII-
antagonist treatment, n (%)
2786 (54)
Physician-reported hypolipidaemic treatment 3373 (66)
Eye screening completed 2762 (54)
Foot examination completed 4362 (85)
*Within the year prior to enrolment in the DD2 cohort.
ATII-antagonist, angiotensin 2 antagonist; BMI, body mass 
index; HbA1c, glycosylated haemoglobin A; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein.
Table 3 Continued 
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FIndIngs to dAte
Mortality ratios
The DD2 cohort has been followed for a total of 18 862 
person-years (PY) and a mean of 2.7 years. A total of 212 
patients have died, yielding an all-cause mortality rate 
(MR) of 1.12 per 100 PY (95% CI 0.97 to 1.29), with 
differences by gender (MR for women: 0.81 (95% CI 0.62 
to 1.03); MR for men: 1.36 (95% CI 1.15 to 1.60)). As 
expected, all-cause MR increased with age (table 5).
Table 4 Comorbidities (determined through linkage with 
the DNPR) and use of medications (determined through 
linkage with the DNHSP) at enrolment among the first 
7011* patients with newly diagnosed type 2 diabetes 
enrolled in the DD2 project
Variables
Patients with type 
2 diabetes
Persons enrolled in DD2 by February 
2016, n (%)
7011 (100)
Charlson Comorbidity Index score†
  0 4807 (69)
  1–2 1820 (26)
  3+ 384 (5)
Charlson Comorbidity Index conditions at 
baseline, n (%)
  Myocardial infarction 345 (5)
  Congestive heart failure 283 (4)
  Peripheral vascular disease 309 (4)
  Cerebrovascular disease 465 (7)
  Dementia 13 (0.2)
  Chronic pulmonary disease 510 (7)
  Connective tissue disease 183 (3)
  Ulcer disease 126 (2)
  Mild liver disease 111 (2)
  Hemiplegia 19 (0.3)
  Moderate to severe renal disease 117 (2)
  Any tumour 508 (7)
  Leukaemia 15 (0.2)
  Lymphoma 26 (0.4)
  Moderate to severe liver disease 16 (0.2)
  Metastatic solid tumour 43 (0.6)
  HIV/AIDS 9 (0.1)
Any macrovascular complications 1511 (22)
Any microvascular complications 1035 (15)
  Diabetic neuropathy 230 (3)
  Diabetic retinopathy 682 (10)
  Diabetic nephropathy 209 (3)
Mental disorder (based on discharge and 
treatment codes for mental illness)*
1456 (21)
Antidiabetic treatment, n (%)*‡
  Insulin only 80 (1)
  Insulin and oral antidiabetic treatment 396 (6)
  Oral antidiabetic treatment 5387 (78)
  None 1053 (15)
Glucose-lowering drugs, n (%)*‡
  Biguanides (metformin) 5631 (81)
  Insulin 476 (7)
  Sulfonylureas 463 (7)
  DPP-4 inhibitors 653 (9)
  GLP-1 analogues 378 (5)
  SGLT-2 inhibitors 57 (0.8)
Continued
Variables
Patients with type 
2 diabetes
  Meglitinides 7 (0.1)
  Thiazolidinediones (glitazones) 1 (0.01)
  Alpha-glucosidase inhibitors 4 (0.06)
Antihypertensive treatment excluding 
loopdiuretics, n (%)*‡
4991 (72)
ACE inhibitors or ATII-antagonist treatment, 
n (%)*‡
4157 (60)
Hypolipidaemic treatment, n (%)*‡ 4886 (71)
Oral steroids, n (%)*‡ 430 (6)
*At the time of analysis, full prescription data were available only 
until 31 December 2015. Therefore, variables based on data from 
the DNHSP are for a subcohort numbering 6916 patients.
†Diabetes mellitus not included in the score as it constitutes the 
index disease. Comorbidity categories include DNPR derived data 
on cancer; more detailed cancer data are available from the Danish 
Cancer Registry.
‡Within the last year prior to DD2 enrolment.
ATII-antagonist, angiotensin 2 antagonist; DD2, Danish Centre 
for Strategic Research in Type 2 Diabetes; DNPR, Danish 
National Patient Registry; DNHSP, Danish National Health Service 
Prescription; DPP-4-inhibitors, dipeptidylpeptidase 4 inhibitors; 
GLP-1 analogues, glucagon-like peptide 1 analogues; SGLT-2 
inhibitors, sodium glucose cotransporter 2 inhibitors.
Table 4 Continued 
Table 5 Number of deaths and overall, age-specific and 
gender-specific mortality rates (per 100 person-years) for the 
baseline cohort of 7011 DD2 patients
Variables
Number of 
deaths MR (95% CI)
Total DD2 cohort 212 1.12 (0.97 to 1.29)
Gender
  Women 65 0.81 (0.62 to 1.03)
  Men 147 1.36 (1.15 to 1.60)
Age (years)
  <40 2 0.23 (0.03 to 0.83)
  40–59 37 0.50 (0.35 to 0.69)
  60–79 149 1.47 (1.25 to 1.73)
  ≥80 24 4.97 (3.19 to 7.40)
Median follow-up time from date of enrolment to death or to date 
of latest data extraction from the Civil Registration System was 
2.68 years (IQR: 1.67–3.63 years).
DD2, Danish Centre for Strategic Research in Type 2 Diabetes; MR, 
mortality rate.
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Key findings
Several baseline cross-sectional studies based on prelim-
inary findings for parts of the current DD2 cohort were 
published in 2014–2016.15–20 Parental history of T2D was 
associated with younger age at diagnosis (adjusted prev-
alence ratio (aPR) for age <40 years: 1.66 (95% CI 1.19 
to 2.31); aPR for age 40–60 years: 1.36 (95% CI 1.24 to 
1.48)), as well as poorer glucose control at diagnosis (aPR 
for fasting blood glucose <6.5 mmol/L: 0.80 (95% CI 0.62 
to 1.02) and aPR for fasting blood glucose ≥7.5 mmol/L: 
1.47 (95% CI 1.20 to 1.80)). No associations were observed 
for anthropometric and lifestyle factors, while parental 
history tended to be negatively associated with the high 
beta cell function phenotype18 (aPR 0.79 (95% CI 0.61 
to 1.01)). This suggests that patients with T2D may not 
inherit diabetes primarily as a result of family-learned 
lifestyle habits (physical inactivity and overeating), 
but rather as a result of a constitutional impairment of 
insulin action/secretion.18 In studies of DD2 biobank 
data, a 16% prevalence of elevated ALAT (>38 IU/L for 
women and >50 IU/L for men)15 and a 40% prevalence 
of elevated CRP (>3.0 mg/L)16 have been found among 
newly diagnosed patients with T2D. As well, potentially 
modifiable predictors of elevated ALAT/CRP have been 
identified, including low physical activity (ALAT: relative 
risk (RR) 1.4, 95% CI 1.04 to 1.93; CRP: RR 1.46, 95% CI 
1.11 to 1.91).15 16 Such biomarkers may have an impact on 
the clinical outcome of diabetes, which future prospec-
tive studies using DD2 data will be able to examine.
In another study, patients with incident T2D were 
followed during their first year postdiagnosis. It was found 
that 74% were receiving glucose-lowering therapy, with 
88% receiving monotherapy, mainly metformin. Factors 
associated with receiving any glucose-lowering therapy 
included young age (RR 1.29, 95% CI 1.16 to 1.44), 
central obesity (RR=1.23, 95% CI 1.04 to 1.44), large 
weight gain since youth (RR=1.10, 95% CI 1.03 to 1.18), 
lack of regular physical activity (RR=1.07, 95% CI 1.01 
to 1.15), high baseline fasting blood glucose (RR=1.25, 
95% CI 1.10 to 1.42) and high comorbidity burden 
(RR=1.20, 95% CI 1.05 to 1.38).17
A publication list is provided at www. dd2. nu. The 
results of many ongoing long-term prospective studies 
will be reported in years to come including genotype 
studies investigating the association between genotypes 
and pharmacological treatment strategies on relevant 
endpoints like glycaemic control and albuminuria.
strengths And lIMItAtIons
The DD2 project has established a large popula-
tion-based cohort of newly diagnosed patients with T2D, 
with demographic, anthropometric, lifestyle and clin-
ical data. Furthermore, the project maintains a valuable 
biobank. Use of the unique individual-level CPR identi-
fier makes it possible to avoid multiple registrations and 
to take advantage of existing data in Danish health and 
administrative registries in a cost-effective way. These 
registries also provide a source of long-term follow-up 
data. Since much of the data are recorded by health 
personnel during diagnosis and treatment, and not for 
research purposes, investigator bias is reduced. In addi-
tion, the validity of Danish registry data is high. As an 
example, reporting of cancer to the DCR is mandatory, 
and completeness is secured by cross-checking with other 
registries including DRCD and the Danish Pathology 
Registry.11 21 In the DNPR, the positive predictive value 
of, for example, hospital discharge diagnoses included in 
the CCI is 94%–100%.22
A few limitations of the DD2 cohort must be noted. 
First, while DD2 and DDDA data are nearly complete 
for demographic variables and for many clinical vari-
ables such as smoking, physical activity, hip–waist ratio 
and resting heart rate, the proportion of missing data is 
large for some variables. For example, in the DDDA, BMI 
is missing for 26% of women. However, waist–hip ratio 
is available for 100% of the DD2 cohort and constitutes 
a better predictor of cardiovascular complications than 
BMI.23 Second, linkage to the DDDA currently is only 
possible for 73% of DD2 participants, partly explained 
by the data delay associated with the DDDA’s role as a 
clinical quality improvement registry. Its mandate is to 
report on quality of care based on data collected during 
the previous year (ie, patients need to have prevalent T2D 
for 1–2 years before they are eligible for quality-of-care 
assessment). In contrast, the DD2 project focuses on 
incident T2D and is tasked with collecting data at time 
of diagnosis.7 Moreover, while reporting to the DDDA 
by GPs became mandatory in 2013, all GP reporting 
discontinued in September 2014 due to conflicting inter-
pretation of legal issues concerning automated data trans-
mission. Third, while it was planned for the DD2 cohort 
to recruit newly diagnosed T2D patients, approximately 
85% already have initiated glucose-lowering treatment at 
enrolment. This hampers analyses of biomarkers among 
treatment-naive patients with T2D. However, the exact 
start date of glucose-lowering therapy can be ascertained 
from prescription registries. Fourth, since predominantly 
patients from outpatient specialist clinics were enrolled 
in early study years, that is, during 2010–2012, the cohort 
initially may have contained newly diagnosed patients with 
T2D with more advanced disease than average. However, 
the baseline data presented in this paper are similar to 
baseline data in a recent registry-based cohort study inves-
tigating patients with T2D from the Northern Region 
of Denmark at initiation of their first glucose-lowering 
therapy,24 thus reassuring that exposures of interest are 
represented for Danish patients withT2D in earlier phases 
of the disease. Finally, a large proportion of patients in 
the DD2 cohort were enrolled during the last few years, 
which limits current opportunities for conducting long-
term follow-up studies.
In the future, the DD2 cohort will serve as a strong 
national and international resource for recruiting patients 
to nested case studies and clinical trials, postmarketing 
surveillance, large-scale genome studies, intervention 
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studies, for example, in patients with rare diabetic 
subtypes, and follow-up studies of diabetes complications.
CollAborAtIon
More information about the DD2 cohort can be found 
at the DD2 website www. dd2. nu. The DD2 project has 
a Steering Group with members from GP practices/
hospital research units in all regions of Denmark. The 
Steering Group strongly encourages national and inter-
national collaboration. Interested researchers can 
contact Director Dr Henning Beck-Nielsen at  henning. 
beck- nielsen@ syd. dk.
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